Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Cash & Current Investments (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Current Investments history spans 7 years, with the latest figure at $357.9 million for Q1 2026.

  • Quarterly Cash & Current Investments fell 25.45% to $357.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $357.9 million through Mar 2026, down 25.45% year-over-year, with the annual reading at $394.0 million for FY2025, 12.07% down from the prior year.
  • Cash & Current Investments came in at $357.9 million for Q1 2026, down from $394.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $547.1 million in Q1 2024 to a low of $63.0 million in Q1 2023.
  • The 5-year median for Cash & Current Investments is $436.6 million (2024), against an average of $367.2 million.
  • Year-over-year, Cash & Current Investments soared 8533.99% in 2022 and then tumbled 37.61% in 2023.
  • MoonLake Immunotherapeutics' Cash & Current Investments stood at $72.1 million in 2022, then soared by 608.6% to $511.0 million in 2023, then fell by 12.32% to $448.0 million in 2024, then dropped by 12.07% to $394.0 million in 2025, then fell by 9.15% to $357.9 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Cash & Current Investments are $357.9 million (Q1 2026), $394.0 million (Q4 2025), and $380.5 million (Q3 2025).